Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Titel:
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Auteur:
Oza, Amit M Lisyanskaya, Alla Fedenko, Alexander de Melo, Andreia Cristina Shparyk, Yaroslav Rakhmatullina, Irina Bondarenko, Igor Colombo, Nicoletta Svintsitskiy, Valentyn Biela, Luciano Nechaeva, Marina Lorusso, Domenica Scambia, Giovanni Cibula, David Póka, Róbert Oaknin, Ana Safra, Tamar Mackowiak-Matejczyk, Beata Ma, Ling Thomas, Daleen Lin, Kevin K McLachlan, Karen Goble, Sandra Kristeleit, Rebecca